|
Sue Siegel brings 25 years experience commercializing key enabling technologies in biomedical research and healthcare. She leads investments in companies focused on personalized medicine, enabling platform technologies for biomedical research, and innovative healthcare companies with disruptive business models. Prior to joining Mohr Davdiow, Sue was President and Director of Affymetrix, Inc., (NASDAQ: AFFX) a company that pioneered GeneChip® technology, which helped accelerate the advent of personalized medicine in modern medicine.
As a member of the Presidents' Circle of the National Academies, Sue serves as an advisor to the Institute of Medicine. She is board member emeritus of The Silicon Valley Tech Museum, serves on The Gladstone Institutes Advisory Council and the Stanford ITI Council, is a YPO member, and a Henry Crown Fellow of the Aspen Institute. As part of the Crown Fellowship, Sue and her husband co-founded with Stanford Hospital, Checking-In™, an organization dedicated to serving our aging population.
Sue received a M.S. in Biochemistry and Molecular Biology from Boston University Medical School where she studied cellular differentiation in mouse embryonic carcinoma stem cells. She received her B.S. in Biology from the University of Puerto Rico.
INVESTMENTS
Corventis
Crescendo Bioscience
Navigenics
On-Q-ity
Pacific Biosciences
RainDance Technologies
< Back to Team Main
|
